Background
What it is, how it developed and why it is discussed
This combination brings together two experimental peptide pathways commonly discussed in recovery settings. Combining them does not establish effectiveness, and robust human trial evidence for the combination is lacking.
Evidence
Evidence, limitations and clinical context
Both BPC-157 and TB-500 are named in SAHPRA public information on illegally marketed peptides. The combination is not available for routine online purchase.
Clinical access
Not available for routine online purchase
This treatment is not enabled for routine online sale. A doctor can discuss the evidence, suitability and lawful alternatives. Where an unregistered medicine is considered clinically necessary, any access must follow the applicable SAHPRA authorisation process before supply.
Clinical assessment Clinician authorisation
